Long‐term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease
- 24 March 2017
- journal article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (4) , 481-488
Abstract
To assess the long-term efficacy and tolerability of mycophenolate mofetil (MMF) in patients with diffuse cutaneous systemic sclerosis (dcSSc). Patients enrolled in the Australian Scleroderma Cohort study with dcSSc and baseline modified Rodnan skin score (mRSS) ≥ 12 who were treated for a minimum of 12 months with MMF for the primary indication of skin disease were included and their prospectively collected data retrieved. Change in mRSS, the proportion with a clinically significant improvement (reduction in mRSS ≥ 5 from baseline) and adverse effects due to therapy were determined. Seventy-four participants treated with MMF were identified and of these, 42 met inclusion criteria. The mean age was 53 ± 12 years, with mean disease duration at MMF commencement of 4.8 ± 4.3 years. Twenty-one participants (50%) commenced MMF within 2 years of disease onset and the mean duration of therapy was 2.7 ± 1.7 years. The mean mRSS at baseline was 25.9 ± 9.2 with a reduction of 3.7 ± 7.1 (P = 0.07) after 1 year of therapy, 7.6 ± 8.3 after 2 years (P = 0.01) and 10.5 ± 10.3 after 5 years (P < 0.01). Response to treatment was not affected by disease duration at MMF commencement or baseline skin score. Eighteen participants (43%) demonstrated clinically significant improvement after 1 year, increasing to 92% after 4 years. Two participants (5%) ceased MMF due to adverse effects. MMF was associated with a modest improvement in mRSS and was well tolerated in the treatment of dcSSc. Given the natural history of dcSSc where skin involvement can spontaneously improve, randomized, placebo-controlled studies are required to confirm whether improvement can be attributed to MMF therapy.Keywords
Funding Information
- Arthritis Australia
- GlaxoSmithKline
- Pfizer
This publication has 22 references indexed in Scilit:
- Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung DiseaseThe Journal of Rheumatology, 2013
- Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosisAnnals of the Rheumatic Diseases, 2011
- The Anti-Fibrotic Effect of Mycophenolic Acid–Induced Neutral EndopeptidaseJournal of the American Society of Nephrology, 2010
- Evidence-based management of rapidly progressing systemic sclerosisBest Practice & Research Clinical Rheumatology, 2010
- A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosisRheumatology, 2009
- Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double‐blind, randomized controlled trialsArthritis & Rheumatism, 2009
- EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)Annals of the Rheumatic Diseases, 2009
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisAnnals of the Rheumatic Diseases, 2007
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001